Summit Therapeutics PLC (NASDAQ:SMMT)

2.44
BATS BZX Real-Time Price
As of 2:40pm ET
 +0.17 / +7.49%
Today’s Change
2.16
Today|||52-Week Range
16.86
-77.98%
Year-to-Date
Zogenix's Epilepsy Candidate Successful in Phase III Study
Jul 13 / Zacks.com - Paid Partner Content
KemPharm Stock Down Despite Positive Data on ADHD Candidate
Jul 10 / Zacks.com - Paid Partner Content
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
Jul 11 / Zacks.com - Paid Partner Content
Summit Therapeutics Enters Oversold Territory
Jul 10 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close2.27
Today’s open2.38
Day’s range2.30 - 2.44
Volume13,670
Average volume (3 months)108,685
Market cap$35.6M
Data as of 2:40pm ET, 07/20/2018

Growth & Valuation

Earnings growth (last year)+69.34%
Earnings growth (this year)-67.06%
Earnings growth (next 5 years)--
Revenue growth (last year)+970.39%
P/E ratioNM
Price/Sales5.44
Price/Book2.27

Competitors

 Today’s
change
Today’s
% change
MLNTMelinta Therapeutics...-0.09-1.48%
ACRXAcelRx Pharmaceutica...+0.02+0.85%
CDMOAvid Bioservices Inc+0.35+6.17%
RDHLRedhill Biopharma Lt...-0.19-1.84%
Data as of 2:44pm ET, 07/20/2018

Financials

Next reporting dateSeptember 6, 2018
EPS forecast (this quarter)-$0.51
Annual revenue (last year)$33.0M
Annual profit (last year)-$9.3M
Net profit margin-28.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Executive Director
Glyn Owain Edwards
Chief Operating &
Medical Officer
David Roblin
Corporate headquarters
Abingdon, Oxfordshire

Forecasts